Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis.
Recently, there have been reports on the efficacy of low-density lipoprotein (LDL) apheresis (LDL-A) for focal and segmental glomerulosclerosis (FSGS) in pediatric patients. However, there have been few reports on the long-term efficacy of LDL-A for FSGS in such patients. We report here a case of long-term efficacy of LDL-A for FSGS. The patient was a 13-year-old boy with FSGS who presented with steroid-resistant and cyclosporine-resistant nephrotic syndrome and hyperlipidemia. LDL-A was performed 24 times on one year. Following LDL-A, serum concentrations of LDL, very low-density lipoprotein (VLDL), apoprotein B, and vascular endothelial growth factor significantly decreased, and urinary excretion of protein also decreased. In addition, 3 years after LDL-A, the pathology findings on a second renal biopsy had improved. The patient has been in remission from FSGS for 12 years since LDL-A. These findings suggest that LDL-A may be useful in maintaining long-term remission from pediatric FSGS.
Kawasaki
Yukihiko
Y
Department of Pediatrics, Fukushima Medical University School of Medicine, 1 Hikariga-oka, Fukushima City, Fukushima 960-1295, Japan. tomo@fmu.ac.jp
Suzuki
Sigeo
S
Matsumoto
Ayumi
A
Takano
Kei
K
Suyama
Kazuhide
K
Hashimoto
Koichi
K
Suzuki
Junzo
J
Suzuki
Hitoshi
H
Hosoya
Mitsuaki
M
D000293:Adolescent; D001781:Blood Component Removal; D004351:Drug Resistance; D005923:Glomerulosclerosis, Focal Segmental / Q000097:blood / Q000150:complications / Q000628:therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000628:therapy; D007678:Kidney Glomerulus / Q000473:pathology; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000097:blood / Q000209:etiology / Q000628:therapy; D016896:Treatment Outcome
D008077:Lipoproteins, LDL; D008775:Methylprednisolone